Abstract

The present study reports an immunohistochemical approach for localizing the immunoreactivity of vasoactive intestinal polypeptide (VIP) receptor in the human colon, by using a monoclonal antibody which recognizes the VIP-receptor of a human colonic adenocarcinoma cell line. Simultaneous demonstration of immunoreactive VIP-receptor of a human colonic adenocarcinoma cell line. Simultaneous demonstration of immunoreactive VIP-receptor and VIP was achieved by a double-labelling procedure employing immunogold silver staining for VIP-receptor, and a biotinylated secondary antibody followed by streptavidin-Texas Red, to visualize VIP. The immunoreactive VIP receptor was found at two locations receiving dense VIP innervation: myenteric ganglia and mucosal epithelium. Epithelial cells displayed intense labelling at the basolateral membrane, which confirmed earlier binding studies on fractionated membranes. A small number of enteroendocrine cells was also recognized by the VIP-receptor antibody. Smooth muscle and cells of the immune system were not stained by the monoclonal antibody, indicating that it recognized an epitope not common to VIP-receptors of all locations. Thus, the immunohistochemical approach of VIP-receptor localization differs from autoradiography in (a) precise cellular localization, (b) possibility of simultaneous demonstration of receptor and ligand immunoreactivity, and (c) selectivity to a certain receptor population which, however, is presently not fully characterized.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.